The global tetanus toxoid vaccine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Tetanus (popularly known by the name as lockjaw disease) is a non-communicable severe disease which is caused by a bacterial toxin primarily affecting the nervous system. The disease leads to aching muscle contractions, specifically the jaw and neck muscles with symptoms such as paralysis of the jaw, back pain, muscle stiffness, spasms, and difficulties in breathing. The bacterial (Clostridium tetani or the C. tetani) career include soil, human and animal stools, and street dust. The enteral mode of bacteria in the body occurs through wounds. Thus, the growing cases of injuries among people is a key factor that propels the growth of this vaccine usage among the population as a part of preventative care.

Most cases of tetanus occur in people who have never been vaccinated or in adults who have not kept up with their 10-year booster shots. There are different vaccines that provide protection against tetanus include DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine. Rising cases of tetanus and diphtheria, new products under the clinical trials, and increasing government initiatives regarding vaccination and immunization are the key driving factors of the global tetanus toxoid vaccine market. According to the World Health Organization (WHO), in 2015, about 34,000 newborns died from neonatal tetanus all over the globe. In addition, there were 15,103 reported cases of tetanus and diphtheria were reported in 2018, with an increase from 13,500 tetanus cases in 2016. Since the number of cases have increased in the past few years, the market is likely to grow in the future years.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  GlaxoSmithKline plc, Merck & Co., Inc., and Sanofi S.A., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Tetanus Toxoid Vaccine Market Report by Segment

By Type

    • Diphtheria, Tetanus, and Pertussis (DTaP)

    • Diphtheria and Tetanus (DT)

    • Tetanus, Diphtheria, and Pertussis (Tdap)

    • Others

By Application

    • Hospitals and Clinics

    • Government Organizations

Global Tetanus Toxoid Vaccine Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa